• Publications
  • Influence
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
BACKGROUND Ipilimumab monotherapy (at a dose of 3 mg per kilogram of body weight), as compared with glycoprotein 100, improved overall survival in a phase 3 study involving patients with previouslyExpand
  • 3,661
  • 112
  • PDF
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
BACKGROUND Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600EExpand
  • 4,349
  • 109
  • PDF
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
BACKGROUND The combined inhibition of BRAF and MEK is hypothesized to improve clinical outcomes in patients with melanoma by preventing or delaying the onset of resistance observed with BRAFExpand
  • 1,351
  • 44
  • PDF
Improved survival with MEK inhibition in BRAF-mutated melanoma.
BACKGROUND Activating mutations in serine-threonine protein kinase B-RAF (BRAF) are found in 50% of patients with advanced melanoma. Selective BRAF-inhibitor therapy improves survival, as comparedExpand
  • 1,246
  • 39
  • PDF
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
BACKGROUND Combined BRAF and MEK inhibition, as compared with BRAF inhibition alone, delays the emergence of resistance and reduces toxic effects in patients who have melanoma with BRAF V600E orExpand
  • 1,170
  • 32
  • PDF
Melanoma epidemiology and trends.
Rising incidence rates of cutaneous melanoma have been observed during the last four decades in white populations worldwide. The cancer statistics in the United States have revealed 6 cases perExpand
  • 574
  • 25
Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline.
Cutaneous melanoma (CM) is potentially the most dangerous form of skin tumour and causes 90% of skin cancer mortality. A unique collaboration of multi-disciplinary experts from the EuropeanExpand
  • 352
  • 24
Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.
BACKGROUND The combination of cobimetinib with vemurafenib improves progression-free survival compared with placebo and vemurafenib in previously untreated patients with BRAF(V600)-mutant advancedExpand
  • 458
  • 23
Epidemiology of melanoma and nonmelanoma skin cancer--the role of sunlight.
Melanoma and nonmelanoma skin cancer (NMSC) are now the most common types of cancer in white populations. Both tumor entities show an increasing incidence rate worldwide but a stable or decreasingExpand
  • 608
  • 22
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.
PURPOSE In phase I/II trials, the cytotoxic T lymphocyte-associated antigen-4-blocking monoclonal antibody tremelimumab induced durable responses in a subset of patients with advanced melanoma. ThisExpand
  • 582
  • 17
...
1
2
3
4
5
...